- Home
- ACXP vs SLGL Comparison
ACXP vs SLGL Comparison
Compare ACXP & SLGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACXP
- SLGL
- Stock Information
- Founded
- ACXP 2017
- SLGL 1997
- Country
- ACXP United States
- SLGL Israel
- Employees
- ACXP N/A
- SLGL N/A
- Industry
- ACXP Biotechnology: Pharmaceutical Preparations
- SLGL Biotechnology: Pharmaceutical Preparations
- Sector
- ACXP Health Care
- SLGL Health Care
- Exchange
- ACXP Nasdaq
- SLGL Nasdaq
- Market Cap
- ACXP 8.4M
- SLGL 19.3M
- IPO Year
- ACXP 2021
- SLGL 2018
- Fundamental
- Price
- ACXP $0.49
- SLGL N/A
- Analyst Decision
- ACXP Strong Buy
- SLGL Buy
- Analyst Count
- ACXP 2
- SLGL 1
- Target Price
- ACXP $10.00
- SLGL $40.00
- AVG Volume (30 Days)
- ACXP 18.6M
- SLGL 25.1K
- Earning Date
- ACXP 08-08-2025
- SLGL 08-15-2025
- Dividend Yield
- ACXP N/A
- SLGL N/A
- EPS Growth
- ACXP N/A
- SLGL N/A
- EPS
- ACXP N/A
- SLGL N/A
- Revenue
- ACXP N/A
- SLGL $12,103,000.00
- Revenue This Year
- ACXP N/A
- SLGL N/A
- Revenue Next Year
- ACXP N/A
- SLGL $31.17
- P/E Ratio
- ACXP N/A
- SLGL N/A
- Revenue Growth
- ACXP N/A
- SLGL 603.66
- 52 Week Low
- ACXP $0.30
- SLGL $3.34
- 52 Week High
- ACXP $3.33
- SLGL $16.50
- Technical
- Relative Strength Index (RSI)
- ACXP 51.70
- SLGL 54.45
- Support Level
- ACXP $0.46
- SLGL $7.02
- Resistance Level
- ACXP $0.56
- SLGL $7.48
- Average True Range (ATR)
- ACXP 0.10
- SLGL 0.33
- MACD
- ACXP -0.01
- SLGL 0.01
- Stochastic Oscillator
- ACXP 25.55
- SLGL 45.39
About ACXP Acurx Pharmaceuticals Inc.
Acurx Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing a new class of antibiotics for infections caused by bacteria listed as priority pathogens by the World Health Organization, Centers for Disease Control and Prevention and Food and Drug Administration. The company's approach is to develop antibiotic candidates with a Gram-positive selective spectrum. The Company's segment consists of the development of clinical and preclinical product candidates for the development of the Company's proprietary new therapies.
About SLGL Sol-Gel Technologies Ltd.
Sol-Gel Technologies Ltd is a dermatology company. It is engaged in identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The company's product candidate pipeline includes SGT-610 (Patidegib Gel 2%), a new chemical entity hedgehog signaling pathway blocker, for the chronic use and prevention of new BCC in Gorlin syndrome patients, and the topical drug candidate SGT-210 for the treatment of Darier Disease and other rare keratosis-related indications such as PC, PPK and Olmsted.